[go: up one dir, main page]

DE69904312D1 - Pharmazeutische aerosolformulierung - Google Patents

Pharmazeutische aerosolformulierung

Info

Publication number
DE69904312D1
DE69904312D1 DE69904312T DE69904312T DE69904312D1 DE 69904312 D1 DE69904312 D1 DE 69904312D1 DE 69904312 T DE69904312 T DE 69904312T DE 69904312 T DE69904312 T DE 69904312T DE 69904312 D1 DE69904312 D1 DE 69904312D1
Authority
DE
Germany
Prior art keywords
aerosol formulation
pharmaceutical aerosol
pharmaceutical
formulation
aerosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69904312T
Other languages
English (en)
Other versions
DE69904312T2 (de
Inventor
P Cavaillon
N Llorca
O Louis
P Rosier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808152.4A external-priority patent/GB9808152D0/en
Priority claimed from GBGB9814709.3A external-priority patent/GB9814709D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE69904312D1 publication Critical patent/DE69904312D1/de
Application granted granted Critical
Publication of DE69904312T2 publication Critical patent/DE69904312T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69904312T 1998-04-18 1999-04-15 Pharmazeutische aerosolformulierung Expired - Fee Related DE69904312T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9808152.4A GB9808152D0 (en) 1998-04-18 1998-04-18 Pharmaceutical aerosol formulation
GBGB9814709.3A GB9814709D0 (en) 1998-07-08 1998-07-08 Pharmaceutical aerosol formulation
PCT/EP1999/002535 WO1999053901A1 (en) 1998-04-18 1999-04-15 Pharmaceutical aerosol formulation

Publications (2)

Publication Number Publication Date
DE69904312D1 true DE69904312D1 (de) 2003-01-16
DE69904312T2 DE69904312T2 (de) 2003-10-16

Family

ID=26313483

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69904312T Expired - Fee Related DE69904312T2 (de) 1998-04-18 1999-04-15 Pharmazeutische aerosolformulierung

Country Status (30)

Country Link
US (1) US7521042B2 (de)
EP (1) EP1073417B1 (de)
JP (1) JP2002512183A (de)
KR (1) KR20010042816A (de)
CN (1) CN1145478C (de)
AP (1) AP2000001961A0 (de)
AR (1) AR018183A1 (de)
AT (1) ATE228823T1 (de)
AU (1) AU755066B2 (de)
BR (1) BR9909736A (de)
CA (1) CA2328882A1 (de)
CO (1) CO5021210A1 (de)
DE (1) DE69904312T2 (de)
DK (1) DK1073417T3 (de)
EA (1) EA200000956A1 (de)
EE (1) EE200000608A (de)
ES (1) ES2189410T3 (de)
HR (1) HRP20000689A2 (de)
HU (1) HUP0101608A2 (de)
ID (1) ID27887A (de)
IL (1) IL139087A0 (de)
IS (1) IS5665A (de)
MA (1) MA26621A1 (de)
NO (1) NO20005218L (de)
NZ (1) NZ507619A (de)
PE (1) PE20000433A1 (de)
PL (1) PL343491A1 (de)
PT (1) PT1073417E (de)
TR (1) TR200100144T2 (de)
WO (1) WO1999053901A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
ATE233084T1 (de) * 1999-04-14 2003-03-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung
WO2002043702A2 (en) † 2000-11-30 2002-06-06 Vectura Limited Pharmaceutical compositions for inhalation
EP2298285A3 (de) 2000-11-30 2011-07-27 Vectura Limited Herstellungsverfahren für Partikel zur Verwendung in einer Arzneizusammensetzung
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
AU2003297320B8 (en) * 2002-12-17 2008-02-21 Medimmune, Llc High pressure spray-dry of bioactive materials
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004103348A2 (en) * 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
US7448389B1 (en) 2003-10-10 2008-11-11 Materials Modification, Inc. Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
CN101155590A (zh) * 2005-02-10 2008-04-02 葛兰素集团有限公司 使用预分选技术制备乳糖的方法以及由此形成的药物制剂
CA2653384C (en) 2006-06-30 2017-03-14 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
EP2393488B1 (de) 2009-02-06 2019-06-19 University Of Southern California Therapeutische zusammensetzungen mit monoterpenen
HUE045917T2 (hu) 2009-02-26 2020-01-28 Glaxo Group Ltd 4-{(lR)-2-[(6-(2-[(2,6-Diklórbenzil)-oxi}-etoxi}-hexil)-amino]-l-hidroxietil}-2-(hidroximetil)-fenolt tartalmazó gyógyszerkészítmények
DK2453894T3 (en) 2009-07-15 2016-01-25 Theravance Biopharma R&D Ip Llc Crystalline free base of a biphenyl compound
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
CN104744215B (zh) 2010-03-03 2019-03-15 尼昂克技术公司 包含单萜的药物组合物
EP2570120B1 (de) * 2010-06-08 2017-10-25 Kobe Gakuin Educational Foundation Beschichtete partikel und verfahren zur herstellung beschichteter partikel
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
CN110464718A (zh) 2010-08-27 2019-11-19 尼昂克技术公司 包含poh衍生物的药物组合物
JP6122564B2 (ja) 2010-12-17 2017-04-26 ネオンク テクノロジーズ インク． イソペリリルアルコールの使用方法および装置
CN102366405A (zh) * 2011-10-21 2012-03-07 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的氟替卡松丙酸酯气雾剂制剂
NZ629438A (en) * 2012-02-28 2016-10-28 Iceutica Holdings Inc Inhalable pharmaceutical compositions
LT2968313T (lt) 2013-03-15 2018-05-10 Verona Pharma Plc Vaistų derinys
SI3142701T1 (en) 2014-05-12 2018-08-31 Verona Pharma Plc NEW TREATMENT
CN112142749A (zh) 2015-02-12 2020-12-29 NeOnc技术股份有限公司 紫苏醇衍生物、药物组合物及其用途
CN106546751A (zh) * 2016-11-16 2017-03-29 广州华弘生物科技有限公司 用于检测oct4蛋白的酶联免疫试剂盒
US10858305B2 (en) 2016-11-30 2020-12-08 Neonc Technologies, Inc. Perillyl alcohol-3-bromopyruvate conjugate and methods of treating cancer
US20210228498A1 (en) 2018-02-08 2021-07-29 Neonc Technologies, Inc. Methods of permeabilizing the blood brain barrier

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
EP0257915B1 (de) * 1986-08-11 1993-03-10 Innovata Biomed Limited Mikrokapseln enthaltende pharmazeutische Zusammensetzungen
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE69625813T2 (de) * 1995-06-12 2003-09-04 Ono Pharmaceutical Co. Ltd., Osaka Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
EP0971698A4 (de) * 1996-12-31 2006-07-26 Nektar Therapeutics Aerolisiertes hydrophobisches medikament

Also Published As

Publication number Publication date
TR200100144T2 (tr) 2001-06-21
EE200000608A (et) 2001-08-15
HUP0101608A2 (hu) 2002-03-28
JP2002512183A (ja) 2002-04-23
AU3523199A (en) 1999-11-08
NO20005218L (no) 2000-11-10
CO5021210A1 (es) 2001-03-27
ES2189410T3 (es) 2003-07-01
HRP20000689A2 (en) 2001-02-28
ATE228823T1 (de) 2002-12-15
EA200000956A1 (ru) 2001-04-23
AR018183A1 (es) 2001-10-31
AP2000001961A0 (en) 2000-12-31
IS5665A (is) 2000-10-13
PE20000433A1 (es) 2000-05-26
EP1073417B1 (de) 2002-12-04
IL139087A0 (en) 2001-11-25
PL343491A1 (en) 2001-08-27
EP1073417A1 (de) 2001-02-07
CN1145478C (zh) 2004-04-14
AU755066B2 (en) 2002-12-05
US20030157032A1 (en) 2003-08-21
WO1999053901A1 (en) 1999-10-28
US7521042B2 (en) 2009-04-21
ID27887A (id) 2001-05-03
BR9909736A (pt) 2000-12-19
NO20005218D0 (no) 2000-10-17
CN1305369A (zh) 2001-07-25
CA2328882A1 (en) 1999-10-28
KR20010042816A (ko) 2001-05-25
DE69904312T2 (de) 2003-10-16
MA26621A1 (fr) 2004-12-20
NZ507619A (en) 2003-05-30
DK1073417T3 (da) 2003-03-24
PT1073417E (pt) 2003-04-30

Similar Documents

Publication Publication Date Title
ATE228823T1 (de) Pharmazeutische aerosolformulierung
DE69807420D1 (de) Pharmazeutische aerosolzusammensetzung
DE69812089D1 (de) Pharmazeutische omeprazol-formulierung
DE69525148D1 (de) Pharmazeutische formulierung
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
NO992339L (no) Farmasöytiske formuleringer
NO20012915D0 (no) Ny farmasöytisk formulering
DE69530325D1 (de) Aerosol-arzneiformulierungen
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
DE59915033D1 (de) Pharmazeutische Zubereitung
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
DE69830154D1 (de) Pharmazeutische zusammensetzungen
ID30032A (id) Formulasi farmasi
AR025867A1 (es) Formulacion portasdora farmaceutica
EP1124557A4 (de) Pharmazeutische zusammensetzung
NO20004816D0 (no) Ny farmasøytisk formulering
DE19681529D2 (de) Pharmazeutische Darreichungsform
SE9803952D0 (sv) Pharmaceutical formulation
ATA77096A (de) Pharmazeutische präparation
DK1037604T3 (da) Farmaceutiske aerosolsammensætninger
GB9808152D0 (en) Pharmaceutical aerosol formulation
GB9814709D0 (en) Pharmaceutical aerosol formulation
SI1073417T1 (en) Pharmaceutical aerosol formulation
SE9600141D0 (sv) Pharmaceutical formulation
EP1095026A4 (de) Pharmazeutische mittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee